Every AXLRx NSCLC report, across 6 report types. Each is scoped to your asset and verified to a live source.
Four approved IO agents split 1L NSCLC into three PD-L1 cohorts. Pembrolizumab holds an estimated 52% share ahead of 2028 patent expiry.
How the US NSCLC population segments by histology and biomarker, where it is actually diagnosed and tested, and where the gap between diagnosis and treatment costs patients.
Incidence-to-eligible NSCLC funnel by cohort with sourced conversion assumptions and a share waterfall.
CMS routes all four approved 1L NSCLC IO agents through Part B buy-and-bill at ASP+6%, but PD-L1 assay requirements split coverage into three distinct biomarker-testing tiers.
NSCLC is a specialist, buy-and-bill oncology market — a concentrated medical-oncology prescriber base, biomarker-gated prescribing, and infused immuno-oncology reimbursed under Medicare Part B. That dictates a small, account-based key-account + MSL field model, not a mass-reach primary-care one.
Pembrolizumab holds an estimated 52% of first-line NSCLC on five years of precedent, and payers evaluate every new IO or targeted asset against KEYNOTE, CheckMate, and IMpower coverage policy, not against a fresh trial design.
AXLRx publishes Competitive Intelligence, Disease Landscape, Patient Flow Model, Payer & HTA, Field-Force Strategy, and Launch Readiness for Non-Small Cell Lung Cancer. Each report is scoped to your asset, verified to a live source, and delivered in 72 hours.
Current NSCLC coverage spans United States. Additional markets can be commissioned against the same evidence standard.
Every figure is cited to a live source at the point of writing and re-checked in an independent audit pass. The latest NSCLC reports were updated July 2026.